You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for HEADACHE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HEADACHE

Average Pharmacy Cost for HEADACHE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HEADACHE RELIEF CAPLET 70000-0146-01 0.06280 EACH 2025-01-22
HEADACHE RLF 250-250-65 MG CPLT 70000-0066-01 0.06280 EACH 2025-01-22
HEADACHE RELIEF CAPLET 70000-0146-01 0.06407 EACH 2024-12-18
HEADACHE RLF 250-250-65 MG CPLT 70000-0066-01 0.06407 EACH 2024-12-18
HEADACHE RELIEF CAPLET 70000-0146-01 0.06295 EACH 2024-11-20
HEADACHE RLF 250-250-65 MG CPLT 70000-0066-01 0.06295 EACH 2024-11-20
HEADACHE RELIEF CAPLET 70000-0146-01 0.06531 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Migraine Drugs Market Analysis and Price Projections

Market Overview

The migraine drugs market is experiencing significant growth, driven by the increasing prevalence of migraines and the approval of new, effective treatments. Here are the key points to consider:

Market Size and Growth

  • The global migraine drugs market was valued at approximately USD 5.64 billion in 2023 and is projected to grow at a CAGR of 11.9% from 2024 to 2030[1].
  • Another estimate suggests the market size was USD 6.2 billion in 2023, growing at a CAGR of 6.7% from 2024 to 2032[3].

Prevalence and Demographics

  • Migraines affect approximately 40% of the global population, or around 3.1 billion individuals, with a higher prevalence among females due to hormonal imbalances[1][3].
  • Headache disorders, including migraines, are among the top three most frequent neurological conditions across various age groups[1].

Drug Classes and Treatment Options

Prescription Drugs

  • Prescription drugs led the market, accounting for 78.10% of the global revenue in 2023. This segment is anticipated to grow significantly due to the rising prevalence of migraines and the demand for effective medications[1].

CGRP Antagonists and Gepants

  • Calcitonin gene-related peptide (CGRP) antagonists, including monoclonal antibodies (mAbs) and oral gepants, are driving market growth. These drugs are used for both acute and preventive treatment and have higher annual costs compared to traditional generic drugs[2].
  • Examples of approved CGRP-targeting drugs include Rimegepant, Ubrogepant, Zavegepant, and Atogepant[1].

Other Treatment Options

  • Traditional drug classes such as triptans for acute treatment and antidepressants, anticonvulsants, and beta blockers for prevention are still in use but are being gradually replaced by CGRP antagonists and gepants due to their superior efficacy and tolerability[2].

Regional Insights

  • North America dominates the market, accounting for 40.91% of the global share in 2023, due to the high prevalence of migraines in the region. For instance, about 1 in every 4 American households has a member suffering from migraines[1].
  • The Asia Pacific region is expected to grow significantly, with a CAGR of 7.1% during the forecast period[3].

Market Dynamics and Challenges

Growth Drivers

  • The increasing incidence of migraines, advancements in pharmaceutical solutions, and rising demand for fast-acting and effective treatments are key drivers of the market[5].
  • Novel drug delivery systems and patient preference for rapid-acting solutions are also contributing to market growth[3][5].

Challenges

  • High costs associated with advanced therapies, such as CGRP antagonists, pose a challenge due to reimbursement restrictions and potential generic erosion once patents expire[2][5].
  • Despite the efficacy of new therapies, there remains an unmet need for novel preventive treatments, as not all patients respond to current options[2].

Pipeline and Future Outlook

  • Several late-stage pipeline products are expected to enter the market, including those targeting acute treatment and preventive therapies. Notably, Lundbeck’s anti-pituitary adenylate cyclase-activating polypeptide (PACAP) mAb, LuAG-09222, is seen as a promising therapy to address the unmet need for novel preventive treatments[2].

Competitive Landscape

  • The market is characterized by the presence of established pharmaceutical companies engaging in strategic initiatives such as collaborations, product launches, and investments to strengthen their product portfolios[3].

Price Projections

  • The global migraine drugs market is expected to reach USD 16.4 billion by 2033 across the seven major markets (7MM), growing at a CAGR of 6.0% from 2023[2].
  • The acute migraine drugs market is projected to grow at a CAGR of 8.58% from 2023 to 2030, reaching USD 8.75 billion by the end of the forecast period[5].

Top-Selling Drugs

  • AbbVie’s Ubrelvy (ubrogepant) is expected to be the top-selling drug in the migraine market in 2033, with sales of $1.07 billion. Pfizer’s Nurtec, approved for both acute and preventive therapy, is expected to peak with the highest sales of $1.96 billion in 2029 before its patent expires[2].

Key Takeaways

  • The migraine drugs market is driven by the increasing prevalence of migraines and the approval of new, effective treatments.
  • CGRP antagonists and gepants are key drivers of market growth due to their superior efficacy and tolerability.
  • Regional markets, particularly North America and the Asia Pacific, are expected to contribute significantly to the market's growth.
  • High costs and reimbursement restrictions are challenges, but the pipeline of new therapies offers promising future outlooks.
  • Patient preference for rapid-acting solutions is shaping research priorities and product introductions.

FAQs

1. What is the current size of the global migraine drugs market?

The global migraine drugs market was valued at approximately USD 5.64 billion in 2023[1].

2. What is the projected growth rate of the migraine drugs market?

The market is projected to grow at a CAGR of 11.9% from 2024 to 2030[1].

3. Which drug classes are leading the market growth?

CGRP antagonists, including monoclonal antibodies (mAbs) and oral gepants, are driving the market growth due to their superior efficacy and tolerability[2].

4. What are the main challenges facing the migraine drugs market?

High costs associated with advanced therapies and reimbursement restrictions are significant challenges. Additionally, not all patients respond to current therapies, highlighting an unmet need for novel preventive treatments[2][5].

5. Which region dominates the migraine drugs market?

North America dominates the market, accounting for 40.91% of the global share in 2023[1].

Cited Sources:

  1. Grand View Research - Migraine Drugs Market Size, Share & Trends Report, 2030
  2. Clinical Trials Arena - Migraine market expected to reach $16.4bn across 7MM by 2033
  3. GMI Insights - Migraine Drugs Market Size & Share Report, 2024 – 2032
  4. Allied Market Research - Migraine Drugs Market Size, Share & Report 2035
  5. GlobeNewswire - Acute Migraine Drugs Market is expected to generate a revenue of USD 8.75 Billion by 2030 Globally at 8.58 CAGR

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.